Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2005-02-08
Wessendorf, T. D. (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C530S327000, C530S300000, C514S014800, C514S002600
Reexamination Certificate
active
06852696
ABSTRACT:
The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of glycosaminoglycan-mediated signaling events and targeting agents. Peptides of the invention may be directed against any glycosaminoglycan, including hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2. The peptide derivatives of the invention also have therapeutic uses in the treatment and prevention of diseases involving inflammatory diseases, cancer, and cancer metastasis, autoimmune diseases, etc.
REFERENCES:
patent: 20020042386 (2002-04-01), Rosen et al.
patent: 0950708 (1999-10-01), None
patent: WO 9321312 (1993-10-01), None
patent: WO 9511924 (1995-05-01), None
patent: WO 9709051 (1997-03-01), None
patent: WO 0001841 (2000-01-01), None
patent: WO 0068263 (2000-11-01), None
Van Kuppelt et al., (1998),J. Biol. Chem.,273(21):12960-12966.
Liang et al., (1997),FEBS.,407:169-172.
Kubens et al., (1997),Cancer Lett.,118:189-200.
Accession Number Smart 00445 at the NCBI Structure database, www.Ncbi.nlm.nih.gov.
Aruffo, et al. “CD44 is the principal cell surface receptor for hyaluronate”,Cell,(1990) vol. 61: 1303-1313.
Barbas, et al. “Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem.”Proc. Natl. Acad. Sci. USA,(1992) vol. 89: 4457-4461.
Bartolazzi, et al. “Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development”,J. Exp. Med.,(1994) vol. 180: 53-66.
Bensouyad, et al. “Concentrations of glycosaminoglycans in synovial fluids and their relation with immunological and inflammatory mediators in rheumatoid arthritis”,Ann. Rheum. Dis.,(1990) vol. 49: 301-307.
Bertrand, et al. “Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas; Comparison between invasive and non-invasive areas”,Int. J. Cancer.,(1992) vol. 52: 1-6.
Camp, et al. “CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation”,J. Exp. Med.,(1993) vol. 178: 497-507.
Culty, et al. “The hyaluronate receptor is a member or the CD44 (H-CAM) family of cell surface glycoproteins”,J. Cell. Biol.,(1990) vol. 111: 2765.
Degrendele, et al. “CD44 and its Ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway”,J. Exp. Med.,(1996) vol. 183: 1119-1130.
Degrendele, et al. “CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation”,J. Immunol.,(1997) vol. 159: 2549-2553.
Degrendele, et al. “Requirement for CD44 in activated T cell extravasation into an inflammatory site”,Science,(1997b) vol. 278: 672-675.
Delpech, et al. “Characterization and purification from human brain of a hyaluronic acid-binding glycoproteins, hyaluronectin”,J. Neurochem.(1981) vol. 36: 855-859.
Dougherty, et al. “Ligand binding specificity of alternatively spliced CD44 isoforms-recognition and binding of hyaluronan by CD44R1”,The Journal of Biological Chemistry,(1994) vol. 269(12): 9074-9078.
Garrard et al., “Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops.”Gene,(1993) vol. 128: 103-109.
Gmachl, et al. “The human sperm protein PH-20 has hyaluronidase activity”,F.E.B.S. Lett.,(1993) vol. 336: 545-548.
Guo, et al. “Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody”, Cancer Res., (1994) vol. 54:1561.
Hardingham, et al. “The role of link-protein in the structure of cartilage proteoglycan aggregates”,Biochem. J.,(1979) vol. 177:237-247.
Hardwick, et al. “Molecular cloning of a novel hyaluronan receptor”,J. Cell. Biol.,(1992) vol. 117: 1343-1350.
Horton, et al. “Hyaluronan fragments synergize with interferon-γ to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophage”,J. Biol. Chem.,(1998) vol. 273: 35088-35094.
Horton, et al. “Regulation of hyaluronan-induced chemokines gene expression by IL-10 and IFN-γ in mouse macrophage”,J. Immunol.,(1998) vol. 160: 3023-3030.
Itano, et al. “Molecular cloning of human hyaluron synthase”,Biochem. Biophys. Res. Commun.,(1996) vol. 222: 816-820.
Kimata, et al. “Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential”,Cancer. Res.,(1983) vol. 43: 1347-1354.
Knudson, et al. “Hyaluronan-binding proteins in development, tissue homeostasis, and disease”,F.A.S.E.B. J.,(1993) vol. 7: 1233-1241.
Knupfer, et al. “Hyaluronic acid binding capacity of malignant glioma cells”,Anticancer. Res.,(1998) vol. 18: 353-356.
Laurent, et al. “Hyaluronan”,F.A.S.E.B. J.,(1992) vol. 6: 2397-2404.
Le Baron, et al. “Hyaluronate binding properties of versican”,J. Biol. Chem.,(1992) vol. 267: 10003-10010.
Lepperdinger, et al. “HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity”,J. Biol. Chem.,(1998) vol. 273: 22466-22470.
Levesque, et al. “In vitro culture of human peripheral blood monocytes induces hyaluronan binding and up-regulates monocyte variant CD44 isoform expression”,The Journal of Immunology,(1996) vol. 156: 1557-1565.
McKee, et al. “Hyaluronan (HA) fragments induce chemokines gene expression in alveolar macrophages”,J. Clin. Invest.,(1996) vol. 98: 2403-2413.
Mikecz, et al. “Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis”,Nat. Med.,(1995) vol. 1: 558-563.
Miyake, et al. “Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition”,J. Exp. Med.,(1990) vol. 172: 69-75.
Mohamadzadeh, et al. “Functional roles for granzymes in murine epidermal gamma (delta) T-cell-mediated killing of tumor targets”,J. Invest. Dermatol.,(1996) vol. 107(5): 738-742.
Mummert, et al. “Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking”,J. Exp. Med.,(2000) vol. 192(6): 769-779.
Ozello, et al. “Growth-promoting activity of acid mucopolysaccharides on a strain of human mammary carcinoma cells”,Cancer. Res.,(1960) vol. 20: 600-604.
Ranganathan, et al. “Hyaluronan mediates sperm motility by enhancing phosphorylation of proteins including hyaluronan binding protein”,Cell. Mol. Biol. Res.,(1995) vol. 41: 467-476.
Rauch, et al. “Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain”,J. Biol. Chem.,(1992) vol. 267: 19536-19547.
Schubert,et al. “Collaborative interactions between growth factors and the extracellular matrix”,Trends Cell. Biol.,(1992) vol. 2: 63-66.
Spelling, et al. “Glycosaminoglycans in the synovial fluids of patients with juvenile rheumatoid arthritis”,Clin. Exp. Rheumatol.,(1991) vol. 9: 195-199.
Spicer, et al. “Molecular cloning and characterization of a putative mouse hyaluronan synthase”,J. Biol. Chem.,(1996) vol. 271: 23400-23406.
Steinman. “The dendritic cell system and its role in immunogenicity”,Ann. Rev. Immunol.,(1991) vol. 9: 271-296.
Takashima, et al. “New technologies to prevent and treat contact hypersensitivity responses”,Ann. N Y Acad. Sci.,(2000) vol. 919: 205-213.
Takeucki, et al. “Variation in glycosaminoglycan components of breast tumors&
Mummert Mark E.
Takashima Akira
Bozicevic Field & Francis LLP
Keddie James S.
The University of Texas System
Wessendorf T. D.
LandOfFree
Inhibitors of glycosaminoglycans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glycosaminoglycans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glycosaminoglycans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509259